ALPHA COGNITION INC (ACOG) Stock Fundamental Analysis

NASDAQ:ACOG • CA02074J5017

5.3 USD
+0.09 (+1.73%)
Last: Feb 12, 2026, 08:27 PM
Fundamental Rating

2

Taking everything into account, ACOG scores 2 out of 10 in our fundamental rating. ACOG was compared to 523 industry peers in the Biotechnology industry. While ACOG has a great health rating, there are worries on its profitability. ACOG has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ACOG had negative earnings in the past year.
  • In the past year ACOG has reported a negative cash flow from operations.
  • In the past 5 years ACOG always reported negative net income.
  • ACOG had a negative operating cash flow in each of the past 5 years.
ACOG Yearly Net Income VS EBIT VS OCF VS FCFACOG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • With a Return On Assets value of -42.06%, ACOG perfoms like the industry average, outperforming 57.36% of the companies in the same industry.
  • With a decent Return On Equity value of -57.42%, ACOG is doing good in the industry, outperforming 62.33% of the companies in the same industry.
Industry RankSector Rank
ROA -42.06%
ROE -57.42%
ROIC N/A
ROA(3y)-333.55%
ROA(5y)-244.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACOG Yearly ROA, ROE, ROICACOG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

  • ACOG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACOG Yearly Profit, Operating, Gross MarginsACOG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

7

2. Health

2.1 Basic Checks

  • ACOG has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for ACOG has been reduced compared to a year ago.
ACOG Yearly Shares OutstandingACOG Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
ACOG Yearly Total Debt VS Total AssetsACOG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • An Altman-Z score of 2.70 indicates that ACOG is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • ACOG has a Altman-Z score of 2.70. This is in the better half of the industry: ACOG outperforms 67.88% of its industry peers.
  • There is no outstanding debt for ACOG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.7
ROIC/WACCN/A
WACCN/A
ACOG Yearly LT Debt VS Equity VS FCFACOG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

  • A Current Ratio of 6.69 indicates that ACOG has no problem at all paying its short term obligations.
  • ACOG's Current ratio of 6.69 is fine compared to the rest of the industry. ACOG outperforms 67.88% of its industry peers.
  • ACOG has a Quick Ratio of 6.03. This indicates that ACOG is financially healthy and has no problem in meeting its short term obligations.
  • ACOG has a better Quick ratio (6.03) than 64.24% of its industry peers.
Industry RankSector Rank
Current Ratio 6.69
Quick Ratio 6.03
ACOG Yearly Current Assets VS Current LiabilitesACOG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

0

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 52.00% over the past year.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ACOG is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -306.97% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1293.75%
EPS Next 2Y-306.97%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACOG Yearly Revenue VS EstimatesACOG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
ACOG Yearly EPS VS EstimatesACOG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2024 2025 2026 -2 -4 -6 -8 -10

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ACOG. In the last year negative earnings were reported.
  • Also next year ACOG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACOG Price Earnings VS Forward Price EarningsACOG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACOG Per share dataACOG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

  • A cheap valuation may be justified as ACOG's earnings are expected to decrease with -306.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-306.97%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

  • No dividends for ACOG!.
Industry RankSector Rank
Dividend Yield 0%

ALPHA COGNITION INC

NASDAQ:ACOG (2/12/2026, 8:27:00 PM)

5.3

+0.09 (+1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)N/A
Inst Owners34.05%
Inst Owner ChangeN/A
Ins Owners9.57%
Ins Owner Change37.98%
Market Cap115.22M
Revenue(TTM)7.43M
Net Income(TTM)-19.47M
Analysts82.86
Price Target18.36 (246.42%)
Short Float %1.51%
Short Ratio3.92
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)28.4%
Min EPS beat(2)-24.95%
Max EPS beat(2)81.76%
EPS beat(4)2
Avg EPS beat(4)32.67%
Min EPS beat(4)-24.95%
Max EPS beat(4)81.76%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)11.14%
Min Revenue beat(2)-14.76%
Max Revenue beat(2)37.04%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.88%
EPS NY rev (1m)0%
EPS NY rev (3m)23.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-41.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-12.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.51
P/FCF N/A
P/OCF N/A
P/B 3.4
P/tB 3.44
EV/EBITDA N/A
EPS(TTM)-1.37
EYN/A
EPS(NY)-1.35
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS0.34
BVpS1.56
TBVpS1.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.06%
ROE -57.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-333.55%
ROA(5y)-244.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.69
Quick Ratio 6.03
Altman-Z 2.7
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)12.76%
Cap/Depr(5y)24.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
EPS Next Y-1293.75%
EPS Next 2Y-306.97%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-49.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year124.69%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-72.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.96%
OCF growth 3YN/A
OCF growth 5YN/A

ALPHA COGNITION INC / ACOG FAQ

Can you provide the ChartMill fundamental rating for ALPHA COGNITION INC?

ChartMill assigns a fundamental rating of 2 / 10 to ACOG.


What is the valuation status of ALPHA COGNITION INC (ACOG) stock?

ChartMill assigns a valuation rating of 0 / 10 to ALPHA COGNITION INC (ACOG). This can be considered as Overvalued.


Can you provide the profitability details for ALPHA COGNITION INC?

ALPHA COGNITION INC (ACOG) has a profitability rating of 1 / 10.


How financially healthy is ALPHA COGNITION INC?

The financial health rating of ALPHA COGNITION INC (ACOG) is 7 / 10.